Dr. Rebecca Baillie to present in Rosa's World-Wide Webinar Series, "Impact of Modeling & Simulation in Drug Development"
Dr. Rebecca Baillie, will present a webinar in Rosa's monthly public webinar series "How to build a PhysioPD model" on June 20, 2011 at 1:00 pm EDT (GMT -5:00).
- (1888PressRelease) June 08, 2011 - Rosa & Co. LLC today announced that Dr. Rebecca Baillie, will present a webinar in Rosa's monthly public webinar series "How to build a PhysioPD model" on June 20, 2011 at 1:00 pm EDT (GMT -5:00). The purpose of the "Impact" series is to foster the use of Modeling and Simulation (M&S) activities in biotechnology, pharmaceutics, and other life science industries. This series will illustrate the advantages and enhancing the applicability of M&S in product discovery, development, and marketing programs. Dr. Baillie's talk, "How to build a PhysioPD model", will provide a scientific background to developing clinically relevant physiologically-based models with an emphasis on using these models in the pharmaceutical decision making process. In particular, this talk will discuss how these models can provide scientific insight and program impact prior to clinical data being available.
Register for this free webinar at www.rosaandco.com/webinar. After registering you will receive a confirmation email containing information about joining the webinar. More information about the webinar series, an archive of past webinars, and a list of future webinar speakers may be found at www.rosaandco.com/webinar.
About Rosa
Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam